Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 3

2600 - Atezolizumab (atezo) vs chemotherapy (chemo) in patients (pts) with platinum-treated locally advanced or metastatic urothelial carcinoma (mUC): a long-term overall survival (OS) and safety update from the Phase III IMvigor211 study

Date

30 Sep 2019

Session

Poster Display session 3

Topics

Tumour Site

Urothelial Cancer

Presenters

Michiel Van der Heijden

Citation

Annals of Oncology (2019) 30 (suppl_5): v356-v402. 10.1093/annonc/mdz249

Authors

M.S. Van der Heijden1, Y. Loriot2, I. Duran3, A. Ravaud4, M.M. Retz5, N.J. Vogelzang6, B. Nelson7, J. Wang7, X. Shen7, T. Powles8

Author affiliations

  • 1 Medical Oncology, Het Nederlands Kanker Instituut Antoni van Leeuwenhoek (NKI-AVL), 1006 BE - Amsterdam/NL
  • 2 Department Of Cancer Medicine, Gustave Roussy, Paris/FR
  • 3 Urology Oncology, Hospital Universitario Marques De Valdecilla, Idival, Santander/ES
  • 4 Oncology, CHU Bordeaux Hopital St. André, 33000 - Bordeaux/FR
  • 5 Urologische, Technische Universitat München, 80333 - München/DE
  • 6 Us Oncology Research, Comprehensive Cancer Centersof NV, 89169 - Las Vegas/US
  • 7 Oncology, Genentech, 94080 - South San Francisco/US
  • 8 Genitourinary Oncology, Barts Cancer Institute, EC1M 6BE - London/GB

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 2600

Background

Atezo (anti–PD-L1) is approved for platinum-treated mUC and other indications. Here, we evaluated long-term OS and safety data from IMvigor211, a randomised study evaluating atezo monotherapy vs chemo in platinum-treated mUC (Powles Lancet 2018; primary analysis median follow-up: ≈ 17 mo).

Methods

Pts with disease progression during or following platinum-based chemo were assigned 1:1 to atezo 1200 mg or chemo (vinflunine, paclitaxel or docetaxel per investigator) IV q3w. OS (primary endpoint) and safety were evaluated descriptively in this ad hoc analysis.

Results

As of 8 Nov 2018, median follow-up was 34.3 mo. OS HRs were similar to those from the primary analysis. 24- and 30-mo OS rates were higher with atezo vs chemo in the intent-to-treat (ITT) and PD-L1 populations (Table). In ITT pts, OS HRs with atezo vs taxanes and vinflunine were 0.73 (95% CI: 0.59, 0.90) and 0.90 (95% CI: 0.74, 1.09), respectively. Grade 3-4 treatment-related adverse events (AEs) occurred in 22% of atezo-treated pts and 43% of chemo-treated pts (Grade 5 treatment-related AEs in 1% vs 2%, respectively). AEs leading to treatment discontinuation occurred in 9% of atezo-treated pts and 18% of chemo-treated pts. 11% of atezo-treated patients had a Grade 3-4 AE of special interest (vs 2% with chemo). 29% and 31% of pts in the atezo and chemo arms, respectively, received ≥ 1 subsequent non-protocol therapy; 8% in the chemo arm had non-protocol immunotherapy.Table:

918P OS in IMvigor211 ITT and PD-L1 populations

PD-L1 IC2/3PD-L1 IC1/2/3ITT
Chemo n = 118Atezo n = 116Chemo n = 309Atezo n = 316Chemo n = 464Atezo n = 467
Number of deaths (% of randomised pts)97 (82)85 (73)269 (87)261 (83)403 (87)386 (83)
Median OS (95% CI), mo10.6 (8.4, 12.2)11.1 (8.6, 15.4)8.2 (7.4, 9.5)8.9 (8.2, 10.9)8.0 (7.2, 8.6)8.6 (7.8, 9.6)
Stratified HR (95% CI)0.87 (0.64, 1.17)0.84 (0.70, 1.00)0.82 (0.71, 0.94)
24-mo OS rate (95% CI)19%33%14%22%13%23%
(12, 27)(24, 42)(10, 17)(18, 27)(10, 16)(19, 26)
30-mo OS rate (95% CI)17%29%10%18%10%18%
(10, 24)(21, 38)(7, 14)(14, 23)(7, 13)(15, 22)

Data cutoff, 8 Nov 2018. Median follow-up, 34.3 mo (range: 0-42.3). Stratification factors: PD-L1 status on tumour-infiltrating immune cells (IC), chemo type, liver metastases, and number of prognostic risk factors. PD-L1 status on IC evaluated per VENTANA SP142 assay.

Conclusions

In this long-term update from IMvigor211, including 24- and 30-mo OS rates, continued OS benefit in favor of atezo vs chemo was observed in the ITT population and in PD-L1 subgroups. No formal statistical comparisons were performed in this ad hoc analysis. Safety results were consistent with those in the primary analysis.

Clinical trial identification

NCT02302807.

Editorial acknowledgement

Jessica Men, PharmD, of Health Interactions, and funded by F. Hoffmann-La Roche, Ltd.

Legal entity responsible for the study

F. Hoffmann-La Roche, Ltd.

Funding

F. Hoffmann-La Roche, Ltd.

Disclosure

M.S. Van der Heijden: Honoraria (institution), Research grant / Funding (institution): Astellas; Honoraria (institution), Research grant / Funding (institution): BMS; Honoraria (institution), Research grant / Funding (institution), Travel / Accommodation / Expenses: Roche; Honoraria (institution), Research grant / Funding (institution): AstraZeneca; Honoraria (institution), Travel / Accommodation / Expenses: MSD; Honoraria (institution): Janssen. Y. Loriot: Advisory / Consultancy: Roche. I. Duran: Research grant / Funding (institution), Travel / Accommodation / Expenses: AstraZeneca; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Roche; Honoraria (self), Advisory / Consultancy: BMS; Honoraria (self), Advisory / Consultancy: MSD; Advisory / Consultancy: Pharmacyclycs; Honoraria (self), Advisory / Consultancy: Janssen; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Ipsen; Honoraria (self), Advisory / Consultancy: Novartis; Honoraria (self): Astellas. A. Ravaud: Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Pfizer; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: AstraZeneca; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: BMS; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Roche; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Ipsen; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Novartis. M.M. Retz: Full / Part-time employment: Technical University Munich, Germany. N.J. Vogelzang: Advisory / Consultancy, Shareholder / Stockholder / Stock options: Caris; Advisory / Consultancy: Merck; Advisory / Consultancy: Pfizer; Advisory / Consultancy: Genentech; Advisory / Consultancy: Esai; Advisory / Consultancy: Tolero; Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Bayer; Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Sanofi; Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Novartis; Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Exelixis; Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Clovis; Travel / Accommodation / Expenses: SWOG; Travel / Accommodation / Expenses: US Oncology. B. Nelson: Shareholder / Stockholder / Stock options, Full / Part-time employment: Roche/GNE. J. Wang: Advisory / Consultancy, Full / Part-time employment: Roche/GNE. X. Shen: Shareholder / Stockholder / Stock options, Full / Part-time employment: Roche/GNE. T. Powles: Honoraria (self), Research grant / Funding (institution), Travel / Accommodation / Expenses: F. Hoffmann-La Roche; Honoraria (self), Research grant / Funding (institution), Travel / Accommodation / Expenses: AstraZeneca; Honoraria (self), Travel / Accommodation / Expenses: BMS; Honoraria (self), Travel / Accommodation / Expenses: Ipsen; Honoraria (self), Travel / Accommodation / Expenses: Exelixis; Honoraria (self), Travel / Accommodation / Expenses: Merck; Honoraria (self), Travel / Accommodation / Expenses: Pfizer; Honoraria (self), Travel / Accommodation / Expenses: Novartis; Honoraria (self), Travel / Accommodation / Expenses: Incyte; Honoraria (self), Travel / Accommodation / Expenses: Seattle Genetics.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.